Xeltis raised €20.5M to advance its aXess vascular access solution toward FDA approval and US commercial launch, with European commercialization ongoing.
- Amount
- $23.3M
- Stage
- Growth
- Announced
- 28 July 2026
- Lead
- Horizon 3 Healthcare
- Other investors
- European Innovation Council, Invest-NL, VI Partners, EQT Life Sciences, DaVita
- Use of funds
- Finalize US pivotal trial of aXess, prepare FDA submission and US launch, roll out in Europe, scale manufacturing, advance XABG and XPAD programs.
- Checked
- Amount and date checked against the press source